2023
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Liedtke C, Mazouni C, Hess K, André F, Tordai A, Mejia J, Symmans W, Gonzalez-Angulo A, Hennessy B, Green M, Cristofanilli M, Hortobagyi G, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2023, 41: 1809-1815. PMID: 36989609, DOI: 10.1200/jco.22.02572.Peer-Reviewed Original ResearchTriple-negative breast cancerPathologic complete response rateNeoadjuvant chemotherapyResidual diseaseBreast cancerProgesterone receptorEstrogen receptorHuman epidermal growth factor receptor 2 (HER2) expressionSurvival rateEpidermal growth factor receptor 2 expressionProgression-free survival ratesM.D. Anderson Cancer CenterComplete response rateOverall survival rateAnderson Cancer CenterReceptor 2 expressionLong-term survivalBone recurrenceNeoadjuvant therapyPostrecurrence survivalVisceral metastasesWorse OSWorse survivalRelapse rateCancer Center
2017
Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer.
Hofstatter E, Horvath S, Chagpar A, Wali V, Bossuyt V, Storniolo A, Patwardhan G, Von Wahlde M, Pusztai L. Comparison of epigenetic aging in normal breast tissue from women with and without breast cancer. Journal Of Clinical Oncology 2017, 35: 1522-1522. DOI: 10.1200/jco.2017.35.15_suppl.1522.Peer-Reviewed Original ResearchNormal breast tissueBreast cancerBreast tissueHealthy peersSusan G. Komen Tissue BankIU Simon Cancer CenterNormal breast tissue samplesBreast cancer preventionCohort of womenImportant risk factorKomen Tissue BankLifetime of womenBreast tissue samplesCurrent medicationsTumor characteristicsCancer CenterRisk factorsCancer preventionClinical dataFamily historyReduction mammoplastyHigh riskChronologic ageReproductive historyCancer
2015
Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer
Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf M, Chung G, Silber A, Hofstatter E, Mougalian S, Epstein L, Hatzis C, Schnabel C, Pusztai L. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. Breast Cancer Research And Treatment 2015, 154: 533-541. PMID: 26578401, PMCID: PMC4661200, DOI: 10.1007/s10549-015-3631-9.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAntineoplastic Agents, HormonalAnxietyBreast NeoplasmsChemotherapy, AdjuvantDecision MakingFemaleGene Expression Regulation, NeoplasticGenetic TestingHumansMiddle AgedNeoplasm Recurrence, LocalPrognosisProspective StudiesReceptors, EstrogenSurveys and QuestionnairesTamoxifenConceptsBreast Cancer IndexExtended endocrine therapyER-positive breast cancerAdjuvant endocrine therapyEndocrine therapyDecisional Conflict ScaleBreast cancerCancer indexPhysician recommendationRisk/benefit discussionEarly-stage estrogen receptorEndocrine therapy trialsYale Cancer CenterPositive breast cancerState-Trait Anxiety Inventory FormMean STAIExtended therapyLate recurrenceAbsolute benefitCancer CenterPatient satisfactionPrognostic informationTreatment recommendationsPatient anxietyImproved outcomes
2012
Survival outcomes in HER2-positive invasive lobular breast carcinoma.
Barcenas C, Hess K, Delpech Y, Pusztai L, Hortobagyi G, Giordano S, Esteva F. Survival outcomes in HER2-positive invasive lobular breast carcinoma. Journal Of Clinical Oncology 2012, 30: 612-612. DOI: 10.1200/jco.2012.30.15_suppl.612.Peer-Reviewed Original ResearchInvasive lobular breast carcinomaDisease-free survivalER/PRInvasive ductal carcinomaLobular breast carcinomaSurvival outcomesOverall survivalBreast carcinomaCox proportional hazards regressionMD Anderson Cancer CenterProgesterone receptor statusRare clinical entityBreast cancer patientsProportional hazards regressionNumber of patientsAnderson Cancer CenterMedian followBetter OSMedian ageReceptor statusClinical entityDuctal carcinomaHazards regressionCancer CenterLobular carcinomaAdjuvant therapy in stage I carcinoma of the breast
Schwartz GF, Reis‐Fihlo J, Pusztai L, Fentiman IS, Holland R, Bartelink H, Rutgers EJ, Solin LJ, Palazzo J, Committee A. Adjuvant therapy in stage I carcinoma of the breast. Cancer 2012, 118: 2031-2038. PMID: 22392361, DOI: 10.1002/cncr.27431.Peer-Reviewed Original ResearchConceptsStage I breast cancerI breast cancerBreast cancerAdjuvant therapyConsensus conferenceStage ILymph node-negative breast cancerNode-negative breast cancerKimmel Cancer CenterAdjuvant chemotherapyAdjuvant hormonesAdjuvant treatmentCancer CenterClinical trialsThomas Jefferson UniversityTreatment criteriaTreatment decisionsIndividual tumorsCancerGenetic factorsChemotherapyMolecular phenotypingTherapyHormoneCurrent data
2011
Effect of CYP2D6 polymorphisms on breast cancer recurrence
Morrow PK, Serna R, Broglio K, Pusztai L, Nikoloff DM, Hillman GR, Fontecha M, Li R, Michaud L, Hortobagyi G, Gonzalez‐Angulo A. Effect of CYP2D6 polymorphisms on breast cancer recurrence. Cancer 2011, 118: 1221-1227. PMID: 21823108, DOI: 10.1002/cncr.26407.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinomaCase-Control StudiesCohort StudiesCytochrome P-450 CYP2D6Cytochrome P-450 CYP2D6 InhibitorsEnzyme InhibitorsFemaleFollow-Up StudiesGenetic Predisposition to DiseaseHumansMastectomyMiddle AgedNeoplasm Recurrence, LocalPolymorphism, GeneticTamoxifenConceptsEarly breast cancerBreast cancer recurrenceAdjuvant tamoxifen therapyCancer recurrenceTamoxifen therapyMedical historyCYP2D6 genotypeTexas MD Anderson Cancer CenterFresh frozen tumor samplesCytochrome P450 2D6 polymorphismMD Anderson Cancer CenterBreast cancer patientsRisk of recurrenceCase-control studyAnderson Cancer CenterPatient's medical historyFrozen tumor samplesAdjuvant tamoxifenAdjuvant therapyConcomitant medicationsPatient characteristicsAmpliChip CYP450 TestCYP2D6 metabolismDisease recurrenceCancer CenterArtificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research And Treatment 2011, 129: 451-458. PMID: 21710134, DOI: 10.1007/s10549-011-1645-5.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsFemaleHumansImmunohistochemistryKaplan-Meier EstimateLinear ModelsMiddle AgedNeoplastic Cells, CirculatingNeural Networks, ComputerPrognosisProportional Hazards ModelsReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneRetrospective StudiesRisk AssessmentRisk FactorsSurvival RateTexasTime FactorsConceptsMetastatic breast cancer patientsRisk of deathBreast cancer patientsCTC countMBC patientsPrognostic effectCancer patientsTumor subtypesTumor cellsMD Anderson Cancer CenterConsecutive MBC patientsTriple-negative MBCMetastatic disease sitesAnderson Cancer CenterTumor molecular subtypeNumber of CTCsMolecular tumor subtypesVisceral metastasesOverall survivalCancer CenterHER2 statusProgesterone receptorMolecular subtypesTherapy typePrognostic tool
2009
A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients
Pusztai L, Rouzier R, Pusztai L, Ibrahim N. A specific nomogram to predict subsequent brain metastasis in metastatic triple-negative breast cancer patients. Journal Of Clinical Oncology 2009, 27: 1028-1028. DOI: 10.1200/jco.2009.27.15_suppl.1028.Peer-Reviewed Original ResearchSubsequent brain metastasesBrain metastasesBreast cancer patientsTN tumorsSpecific nomogramCancer patientsBreast cancerMetastatic triple-negative breast cancer patientsTriple-negative breast cancer patientsD. Anderson Cancer CenterTN breast cancerMetastatic breast cancerAnderson Cancer CenterBM occurrenceMetastatic diseaseMetastatic nodesMetastatic BCInitial diagnosisMetastatic sitesNegative tumorsCancer CenterPreventive treatmentRetrospective analysisFatal eventsHistological characteristics
2008
Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal Of Clinical Oncology 2008, 26: 1275-1281. PMID: 18250347, DOI: 10.1200/jco.2007.14.4147.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsCarcinoma, Ductal, BreastChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoadjuvant TherapyNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualNeoplasms, Hormone-DependentPrognosisProspective StudiesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSurvival RateConceptsTriple-negative breast cancerPathologic complete response rateNeoadjuvant chemotherapyResidual diseaseBreast cancerProgesterone receptorEstrogen receptorHuman epidermal growth factor receptor 2 (HER2) expressionSurvival rateEpidermal growth factor receptor 2 expressionProgression-free survival ratesM.D. Anderson Cancer CenterComplete response rateOverall survival rateAnderson Cancer CenterReceptor 2 expressionLong-term survivalBone recurrenceNeoadjuvant therapyPostrecurrence survivalVisceral metastasesWorse OSWorse survivalRelapse rateCancer Center
2006
Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer
Rouzier R, Pusztai L, Garbay J, Delaloge S, Hunt KK, Hortobagyi GN, Berry D, Kuerer HM. Development and validation of nomograms for predicting residual tumor size and the probability of successful conservative surgery with neoadjuvant chemotherapy for breast cancer. Cancer 2006, 107: 1459-1466. PMID: 16948128, DOI: 10.1002/cncr.22177.Peer-Reviewed Original ResearchConceptsResidual tumor sizeBreast conservation therapyNeoadjuvant chemotherapyBreast conservation surgeryBreast cancer patientsTumor sizeConservation therapyBreast conservationConservation surgeryCancer patientsAnthracycline-based neoadjuvant chemotherapyD. Anderson Cancer CenterPaclitaxel neoadjuvant chemotherapyPreoperative chemotherapy regimenPreoperative chemotherapy regimensSuccessful conservative surgeryValidation of nomogramsInstitut Gustave RoussyAnderson Cancer CenterLogistic regression modelsChemotherapy regimenChemotherapy regimensConservative surgeryClinicopathologic dataCancer Center
2005
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal Of Clinical Oncology 2005, 23: 8331-8339. PMID: 16293864, DOI: 10.1200/jco.2005.01.2898.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDecision Making, Computer-AssistedDisease-Free SurvivalFemaleFranceHumansInternetLogistic ModelsMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNomogramsPaclitaxelPredictive Value of TestsProportional Hazards ModelsReproducibility of ResultsTexasConceptsDistant metastasis-free survivalPathologic complete responseMetastasis-free survivalPreoperative chemotherapyComplete responseCox proportional hazards regression modelProportional hazards regression modelsM.D. Anderson Cancer CenterPreoperative chemotherapy cyclesSchedule of paclitaxelCombination of paclitaxelEstrogen receptor statusHazards regression modelsMultivariate logistic regressionInstitut Gustave RoussyAnderson Cancer CenterInclusion of paclitaxelClinical prediction modelChemotherapy cyclesReceptor statusClinical stageClinical variablesHistologic gradeCancer CenterPrediction nomogramDevelopment of pharmacogenomic markers to select preoperative chemotherapy for breast cancer
Lajos P, Symmans F, Hortobagyi G. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer. Breast Cancer 2005, 12: 73-85. PMID: 15858436, DOI: 10.1007/bf02966817.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual MeetingDevelopment of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer
Pusztai L, Symmans FW, Hortobagyi GN. Development of Pharmacogenomic Markers to Select Preoperative Chemotherapy for Breast Cancer. Breast Cancer 2005, 12: 73-85. DOI: 10.2325/jbcs.12.73.Peer-Reviewed Original ResearchConceptsBreast cancerJapanese Breast Cancer SocietyTexas M. D. Anderson Cancer CenterM. D. Anderson Cancer CenterD. Anderson Cancer CenterEffective adjuvant chemotherapyBreast Cancer SocietyAnderson Cancer CenterAdjuvant chemotherapyCombination of markersPreoperative chemotherapyNew regimensCancer CenterCurrent therapiesBreast centerCancer SocietySmall exploratory studyIndividualized selectionPharmacogenomic markersChemotherapyCancerMolecular characteristicsMarkersTranscriptional profilingAnnual Meeting